Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 1998 Nov;66(11):5450-6.
doi: 10.1128/IAI.66.11.5450-5456.1998.

Murine immune responses to Neisseria meningitidis group C capsular polysaccharide and a thymus-dependent toxoid conjugate vaccine

Affiliations

Murine immune responses to Neisseria meningitidis group C capsular polysaccharide and a thymus-dependent toxoid conjugate vaccine

L J Rubinstein et al. Infect Immun. 1998 Nov.

Abstract

The polysaccharide (PS) capsules of many pathogenic bacteria are poor immunogens in infants and young children as a result of the delayed response to PS antigens during ontogeny. The development of polysaccharide-protein conjugate vaccines for Haemophilus influenzae type b, which have proven to be efficacious in this age group, has led to active development by a number of investigators of conjugate vaccines for other diseases. We describe here the response of several mouse strains to the capsular PS of Neisseria meningitidis group C (MCPS) conjugated to tetanus toxoid (MCPS-TT) and the same response in BALB/c mice as a model of the immune consequences of conjugate vaccine immunization. The use of a conjugate vaccine results in a shift in the isotype elicited in response to the MCPS, from immunoglobulin M (IgM) and IgG3 to primarily IgG1. A response to MCPS-TT is seen even among mouse strains which respond poorly to MCPS itself, emphasizing the importance of a strain survey when choosing a mouse model for a vaccine. The marked increase in IgG1 antibody titer was accompanied by a large increase in bactericidal activity of sera from these animals. Animals primed with the conjugate vaccine demonstrated a booster response after secondary immunization with either the MCPS or the conjugate. The ability to produce a boosted IgG1 anti-MCPS response to the MCPS can be transferred to adoptive recipients by B cells alone from mice primed with MCPS-TT but not mice primed with MCPS alone. These data indicate that in BALB/c mice a single immunization with MCPS-TT is sufficient to induce a shift to IgG1 and generate a memory B-cell population that does not require T cells for boosting.

PubMed Disclaimer

Figures

FIG. 1
FIG. 1
Titers of antibodies specific for MCPS, by IgG subclass, in sera of four strains of mice with different H-2 and Igh haplotypes immunized with MCPS or MCPS-TT and then given boosters of the same antigen. Mice were bled prior to immunization (solid bars), 2 weeks (open bars) and 4 weeks (stippled bars) after primary immunization, and 1 week (crosshatched bars) and 3 weeks (striped bars) after secondary immunization. Some titers were below detectable levels (∗).
FIG. 2
FIG. 2
Titers of antibodies specific for MCPS, by isotype, in sera of BALB/c mice immunized with MCPS or MCPS-TT and given boosters as indicated. Mice were bled prior to immunization (solid bars), 2 weeks (open bars) and 4 weeks (stippled bars) after primary immunization, and 1 week (crosshatched bars) and 3 weeks (striped bars) after secondary immunization. Some titers were below detectable levels (∗).
FIG. 3
FIG. 3
IgG1 antibodies specific for MCPS in sera from irradiated (CBA/N × BALB/c)F1 male mice that were recipients of B cells from BALB/c mice primed with MCPS or MCPS-TT or from unprimed BALB/c mice. The irradiated hosts were given MCPS or MCPS-TT boosters and bled on day 7 after injection. n, number of mice per group. Data are the geometric means ± 99% confidence intervals (CI). Nonoverlapping confidence intervals indicate a significant difference (P ≤ 0.01).

Similar articles

Cited by

References

    1. Aaberge I S, Løvik M. The antibody response to secondary immunization with pneumococcal polysaccharides in mice. Scand J Immunol. 1995;42:617–625. - PubMed
    1. Ahonkhai V I, Lukacs L J, Jonas L C, Matthews H, Vella P P, Ellis R W, Staub J M, Dolan K T, Rusk C M, Calandra G B, Gerety R J. Haemophilus influenzae type b conjugate vaccine (meningococcal protein conjugate) (PedvaxHIB™): clinical evaluation. Pediatrics. 1990;85:676–681. - PubMed
    1. Alonso DeVelasco E, Dekker B A T, Verheul A F M, Feldman R G, Verhoef J, Snippe H. Anti-polysaccharide immunoglobulin isotype levels and opsonic activity of antisera: relationships with protection against Streptococcus pneumoniae infection in mice. J Infect Dis. 1995;172:562–565. - PubMed
    1. Anderson E L, Bowers T, Mink C M, Kennedy D J, Belshe R B, Harakeh H, Pais L, Holder P, Carlone G M. Safety and immunogenicity of meningococcal A and C polysaccharide conjugate vaccine in adults. Infect Immun. 1994;62:3391–3395. - PMC - PubMed
    1. Avery O T, Goebel W F. Chemo-immunological studies on conjugated carbohydrate-proteins. V. The immunological specificity of an antigen prepared by combining the capsular polysaccharide of type III pneumococcus with foreign protein. J Exp Med. 1931;54:437–447. - PMC - PubMed

MeSH terms

LinkOut - more resources